AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

17.11.21	AbbVie: SKYRIZI Gets EU Approval To Treat Adults With Active Psoriatic Arthritis (RTTNews)
17.11.21	AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis (PR Newswire)
15.11.21	Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day (PR Newswire)
10.11.21	AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025 (PR Newswire)
09.11.21	AbbVie Presents Positive Data On Upadacitinib In Active Psoriatic Arthritis And Axial Involvement (RTTNews)
09.11.21	AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021 (PR Newswire)
09.11.21	AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis (PR Newswire)
08.11.21	Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting (PR Newswire)
05.11.21	AbbVie Says Phase 3 Data On Risankizumab Shows Greater Improvements In Psoriatic Arthritis Signs (RTTNews)
05.11.21	AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021 (PR Newswire)
04.11.21	AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting (PR Newswire)
01.11.21	AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021 (PR Newswire)
30.10.21	FDA Approves Allergan's VUITY As First Eye Drop To Treat Presbyopia (RTTNews)
29.10.21	U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) (PR Newswire)
29.10.21	MÄRKTE USA/Leichtes Plus trotz schwacher Zahlen von Apple und Amazon (Dow Jones)
29.10.21	MÄRKTE USA/Apple und Amazon drücken auf die Stimmung (Dow Jones)
29.10.21	MÄRKTE USA/Apple und Amazon belasten Sentiment (Dow Jones)
29.10.21	AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder (RTTNews)
29.10.21	AbbVie Raises FY21 Outlook; Boosts Dividend 8.5% - Quick Facts (RTTNews)
29.10.21	AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder (PR Newswire)
29.10.21	AbbVie Q3 adjusted earnings Beat Estimates (RTTNews)
29.10.21	AbbVie Reports Third-Quarter 2021 Financial Results (PR Newswire)
29.10.21	MARKT USA/Apple und Amazon trüben Stimmung (Dow Jones)
28.10.21	AbbVie: Phase 3 Trial Of ABBV-951 Shows Improvement In Motor Fluctuations In Parkinson's Disease (RTTNews)
28.10.21	AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with A... (PR Newswire)
27.10.21	Ausblick: AbbVie legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
26.10.21	Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia (PR Newswire)
19.10.21	FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira (RTTNews)
15.10.21	AbbVie's Risankizumab Gets CHMP Positive Opinion For Active Psoriatic Arthritis Treatment (RTTNews)
15.10.21	AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) (PR Newswire)
14.10.21	Erste Schätzungen: AbbVie zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
11.10.21	Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness (PR Newswire)
07.10.21	AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies - Quick Facts (RTTNews)
07.10.21	AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis (PR Newswire)
07.10.21	AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis (PR Newswire)
05.10.21	AbbVie to Host Third-Quarter 2021 Earnings Conference Call (PR Newswire)
03.10.21	AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021 (PR Newswire)
30.09.21	AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress (PR Newswire)
30.09.21	AbbVie: New Analysis Show RINVOQ's Potential To Alleviate Itch And Rash In Atopic Dermatitis (RTTNews)
30.09.21	AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress (PR Newswire)
29.09.21	FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine (RTTNews)
29.09.21	FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine (PR Newswire)
27.09.21	Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals (PR Newswire)
23.09.21	AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress (PR Newswire)
20.09.21	AbbVie Seeks Approval For SKYRIZI Based On Data From Three Phase 3 Studies (RTTNews)
20.09.21	AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease (PR Newswire)
16.09.21	AbbVie Files For FDA And EMA Approval Of Upadacitinib For Ulcerative Colitis (RTTNews)
16.09.21	AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
13.09.21	AbbVie Inks Eye Care Deal With REGENXBIO (RTTNews)
13.09.21	AbbVie and REGENXBIO Announce Eye Care Collaboration (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester